HC Wainwright Has Bearish Estimate for COLL Q1 Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Stock analysts at HC Wainwright cut their Q1 2025 EPS estimates for Collegium Pharmaceutical in a report released on Monday, March 24th. HC Wainwright analyst O. Livnat now forecasts that the specialty pharmaceutical company will post earnings per share of $1.20 for the quarter, down from their previous estimate of $1.29. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q2 2025 earnings at $1.48 EPS.

COLL has been the topic of a number of other research reports. Piper Sandler decreased their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Stock Down 1.3 %

COLL stock opened at $29.56 on Wednesday. The business’s 50-day moving average price is $30.43 and its 200-day moving average price is $32.50. The stock has a market cap of $930.73 million, a P/E ratio of 12.74 and a beta of 0.99. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical has a twelve month low of $27.28 and a twelve month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million.

Insider Activity

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 10,445 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the completion of the transaction, the chief financial officer now owns 165,246 shares in the company, valued at $4,959,032.46. This trade represents a 5.95 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the sale, the executive vice president now directly owns 154,204 shares in the company, valued at $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 109,193 shares of company stock worth $3,243,594 over the last quarter. Insiders own 3.98% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. lifted its position in Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company’s stock valued at $50,876,000 after purchasing an additional 289,335 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Collegium Pharmaceutical by 319.4% during the 4th quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company’s stock valued at $8,341,000 after buying an additional 221,903 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after acquiring an additional 175,892 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at about $3,489,000. Finally, Massachusetts Financial Services Co. MA grew its position in Collegium Pharmaceutical by 17.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock worth $29,586,000 after acquiring an additional 116,327 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.